Usefulness of the Nadir Value of Serum Prostate-Specific Antigen Measured by an Ultrasensitive Assay as a Predictor of Biochemical Recurrence after Radical Prostatectomy for Clinically Localized Prostate Cancer

2006 ◽  
Vol 76 (3) ◽  
pp. 227-231 ◽  
Author(s):  
Iori Sakai ◽  
Ken-ichi Harada ◽  
Toshifumi Kurahashi ◽  
Mototsugu Muramaki ◽  
Kazuki Yamanaka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Prostate Specific Antigen ◽  
Biochemical Recurrence ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Serum Prostate Specific Antigen ◽  
Ultrasensitive Assay

Early Detection of Residual Prostate Cancer After Radical Prostatectomy by an Ultrasensitive Assay for Prostate Specific Antigen

1993 ◽  
Vol 149 (4) ◽  
pp. 787-792 ◽  
Author(s):  
Thomas A. Stamey ◽  
Howard C.B. Graves ◽  
Nancy Wehner ◽  
Michelle Ferrari ◽  
Fuad S. Freiha
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Early Detection ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Ultrasensitive Assay

Biochemical Recurrence after Radical Prostatectomy

2018 ◽  
Author(s):  
Dunia Khaled ◽  
Scott Delacroix ◽  
Brian Chapin
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Lymph Node ◽  
Radical Prostatectomy ◽  
Prostate Specific Antigen ◽  
Lymph Node Dissection ◽  
Biochemical Recurrence ◽  
Specific Antigen ◽  
Node Dissection ◽  
Salvage Lymph Node Dissection

After receiving local treatment, many patients will develop a biochemical recurrence (BCR) in the absence of detectable distant disease (cM0) and comprise a significant proportion (20.1%) of prostate cancer disease states. The natural history of patients with BCR ranges from those with indolent, nonprogressive, slow prostate-specific antigen (PSA)-only progression to those ultimately destined to develop metastases and progress to a cancer-specific death. Pathologic predictors of BCR, clinical progression, and cancer-specific mortality are well established in the literature, although multiple novel predictors are emerging, which are highlighted. Traditional imaging cannot reliably distinguish local versus distant microscopic metastasis at the PSA levels that have been shown to confer survival advantage for salvage radiation therapy. We review past and present imaging standards and discuss novel imaging modalities, which may improve staging and offer opportunity for novel salvage therapies, including salvage lymph node dissection and stereotactic beam radiation therapy. With an emphasis on BCR after radical prostatectomy, both curative and palliative treatments are reviewed. This review contains 7 figures, 6 tables and 73 references Key words: biochemical recurrence, clinically undetectable metastases, molecular imaging, monitoring treatment response, prostate cancer, radical prostatectomy, rising prostate-specific antigen, salvage lymph node dissection, salvage radiation  

Sign in / Sign up

Export Citation Format

Share Document